On October 28, 2025, Xi'an Yimcai, Hoyogen Biotech, and BeBetter Pharmaceuticals made their stock market debuts on the Shanghai Stock Exchange. They became the inaugural group of incremental companies within the Growth Tier of the STAR Market. Consequently, the total number of companies in the Growth Tier rose to 35, while the overall count of listed firms on the STAR Market climbed to 592. Back on June 18 of the same year, the China Securities Regulatory Commission (CSRC) unveiled the '1+6' policy initiatives aimed at further advancing the reform of the STAR Market. These measures encompassed the establishment of the Growth Tier and the reinstatement of the fifth set of listing criteria for companies that have not yet achieved profitability. The listing of these three companies serves as a tangible manifestation of the '1+6' reform being put into practice on the STAR Market. It underscores the board's commitment to inclusivity and its robust support for high-tech enterprises. Xi'an Yimcai has emerged as a rising luminary in the semiconductor industry and stands as a frontrunner in the domestic 12-inch silicon wafer sector. Hoyogen Biotech is a global trailblazer in 'rice-based blood production' technology, having secured approval for the market launch of its recombinant human albumin injection product. BeBetter Pharmaceuticals dedicates its efforts to the research and development of innovative drugs targeting major diseases like cancer, with one of its innovative drug products already obtaining market launch approval.